Customizations to the 23rd edition of the MCG Care Guidelines — Chemotherapy and Inpatient & Surgical Care (W0162)
Describes Anthem's customizations to the 23rd edition of the MCG Care Guidelines for adult chemotherapy and inpatient/surgical oncology care, outlining criteria such as aggressive hydration, clinical indications for admission, prolonged marrow suppression, and regimens requiring inpatient management. Affects Anthem providers managing adult oncology patients.
No material clinical or coverage changes in this revision.
Anthem Customizations — Coverage Criteria
Anthem customization topics
Customizations provide specific criteria and guidance on the following topics:
Examples and specific criteria are referenced as being added in the summarized customizations.
No explicit coverage exclusions are stated in the provided excerpt. The document summary indicates only that Anthem implemented customizations to the MCG Care Guidelines (23rd edition) for adult chemotherapy and inpatient & surgical care and lists topics addressed by those customizations; it does not list any items as expressly excluded from coverage.
The excerpt does not specify additional coverage limitations or unspecified coverage details. It summarizes that Anthem’s customizations provide criteria and guidance on topics such as aggressive hydration, clinical indications for admission (including prolonged marrow suppression), and regimens that cannot be managed outpatient, but it does not include further coverage language in the provided text.
| Regimen / Situation | Reason for inpatient management |
|---|---|
| Regimens that cannot be managed outpatient (examples to be added) | Document notes certain chemotherapy regimens require inpatient management; specific examples will be added to the customizations. |
| Regimens associated with aggressive hydration needs | When aggressive hydration cannot be managed in an infusion center, inpatient monitoring and support are required. |
| Regimens with high risk of prolonged marrow suppression | Prolonged marrow suppression is listed as a clinical indication for admission when outpatient management is not appropriate. |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.